Dipòsit Digital de Documents de la UAB
Publication
Artículo científico (JournalArticle)
Can Electronegative LDL Act as a Multienzymatic Complex?
Electronegative LDL (LDL(-)) is a minor form of LDL present in blood for which proportions are increased in pathologies with increased cardiovascular risk. In vitro studies have shown that LDL(-) presents pro-atherogenic properties, including a high susceptibility to aggregation, the ability to induce inflammation and apoptosis, and increased binding to arterial proteoglycans; however, it also shows some anti-atherogenic properties, which suggest a role in controlling the atherosclerotic process. One of the distinctive features of LDL(-) is that it has enzymatic activities with the ability to degrade different lipids. For example, LDL(-) transports platelet-activating factor acetylhydrolase (PAF-AH), which degrades oxidized phospholipids. In addition, two other enzymatic activities are exhibited by LDL(-). The first is type C phospholipase activity, which degrades both lysophosphatidylcholine (LysoPLC-like activity) and sphingomyelin (SMase-like activity). The second is ceramidase activity (CDase-like). Based on the complementarity of the products and substrates of these different activities, this review speculates on the possibility that LDL(-) may act as a sort of multienzymatic complex in which these enzymatic activities exert a concerted action. We hypothesize that LysoPLC/SMase and CDase activities could be generated by conformational changes in apoB-100 and that both activities occur in proximity to PAF-AH, making it feasible to discern a coordinated action among them.
Project:
Ministerio de Economía y Competitividad PI13/00364
,
Ministerio de Economía y Competitividad PI16/00471
,
Instituto de Salud Carlos III PI019/00421
,
Instituto de Salud Carlos III PI20/00334
,
Instituto de Salud Carlos III FI20/00252
,
Instituto de Salud Carlos III CB07/08/0016
,
Instituto de Salud Carlos III RD21/0006/0006
,
Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-1149